---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-23-000047"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:39:18.615266+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q1 revenue $64.8M (+33%), net income $129.1M on $147M Nimbus gain

## Summary
- Drug discovery revenue $32.6M (up 109% YoY) includes $25M BMS milestone for SOS1/KRAS program.
- Software revenue $32.2M (down 3% YoY); gross margin 78%.
- Cash from Nimbus TYK2 sale $147.3M; total cash and securities $532M at quarter-end.
- Phase 1 dosing ongoing for SGR-1505 (MALT1) in B-cell malignancies and healthy volunteers.
- Guidance reaffirmed: software revenue growth 13-17%, drug discovery $70-90M; operating expense growth to moderate.

## SEC filing metadata
- accession: 0001490978-23-000047
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000047/0001490978-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000047/sdgr-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-23-000047
- JSON: https://secwatch.observer/filing/0001490978-23-000047.json
- Plain text: https://secwatch.observer/filing/0001490978-23-000047.txt

## Key facts
- Earnings Releases
  Schrodinger, Inc. reported first quarter 2023 results: revenue $64.8 million, net income $129.1 million. Guidance reaffirmed.
  - Period: first quarter 2023
  - Revenue: $64.8 million
  - Net income: $129.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports Strong First Quarter 2023 Financial Results Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000047/0001490978-23-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.